GILEAD SCIENCES, INC.GILD

Gilead Sciences presents a stark paradox: consistent top-line expansion masked by extreme bottom-line volatility driven by an aggressive, high-cost M&A strategy. While revenue grew steadily from $24.7 billion in FY2020 to $28.8 billion in FY2024, GAAP earnings have been battered by massive one-time charges, culminating in a 92% collapse in net income to just $480 million for FY2024. The central thesis rests on whether the massive cash flows from the dominant HIV franchise can successfully fund a pivot into oncology and liver disease without further eroding shareholder equity through execution errors and asset write-downs.

Beneath the accounting noise, the core business remains a cash-generating engine. The HIV segment delivered $19.6 billion in sales in FY2024, an 8% increase, anchored by Biktarvy, which recently secured exclusivity through 2036. However, the pursuit of growth has been expensive; FY2024 results were decimated by a $4.2 billion impairment for Trodelvy and $3.8 billion in expenses for the CymaBay acquisition. The financial picture stabilized significantly in the first nine months of FY2025, with net income surging to $6.3 billion as impairments did not recur. While Veklury revenue plummeted 60% in Q3 2025, the launch of Livdelzi suggests the underlying portfolio is far stronger than the trough $0.38 EPS recorded at the close of FY2024 implies.